FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557652172> ?p ?o ?g. }

• W2557652172 endingPage "111" @default.
• W2557652172 startingPage "100" @default.
• W2557652172 abstract "Therapy-related myeloid neoplasms are secondary malignancies that are often fatal, but their risk factors are not well understood. Evidence suggests that individuals with clonal haemopoiesis have increased risk of developing haematological malignancies. We aimed to identify whether patients with cancer who have clonal haemopoiesis are at an increased risk of developing therapy-related myeloid neoplasms.We did this retrospective case-control study to compare the prevalence of clonal haemopoiesis between patients treated for cancer who later developed therapy-related myeloid neoplasms (cases) and patients who did not develop these neoplasms (controls). All patients in both case and control groups were treated at MD Anderson Cancer Center (Houston, TX, USA) from 1997 to 2015. We used the institutional medical database to locate these patients. Patients were included as cases if they were treated for a primary cancer, subsequently developed therapy-related myeloid neoplasms, and had available paired samples of bone marrow from the time of therapy-related myeloid neoplasm diagnosis and peripheral blood from the time of primary cancer diagnosis. Patients were eligible for inclusion as age-matched controls if they were treated for lymphoma, received combination chemotherapy, and did not develop therapy-related myeloid neoplasms after at least 5 years of follow-up. We used molecular barcode sequencing of 32 genes on the pretreatment peripheral blood samples to detect clonal haemopoiesis. For cases, we also used targeted gene sequencing on bone marrow samples and investigated clonal evolution from clonal haemopoiesis to the development of therapy-related myeloid neoplasms. To further clarify the association between clonal haemopoiesis and therapy-related myeloid neoplasm development, we also analysed the prevalence of clonal haemopoiesis in an external cohort of patients with lymphoma who were treated in a randomised trial of front-line chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without melatonin. This trial was done at MD Anderson Cancer Center between 1999 and 2001 (protocol number 98-009).We identified 14 cases and 54 controls. Of the 14 cases, we detected clonal haemopoiesis in the peripheral blood samples of ten (71%) patients. We detected clonal haemopoiesis in 17 (31%) of the 54 controls. The cumulative incidence of therapy-related myeloid neoplasms in both cases and controls at 5 years was significantly higher in patients with clonal haemopoiesis (30%, 95% CI 16-51) than in those without (7%, 2-21; p=0·016). In the external cohort, five (7%) of 74 patients developed therapy-related myeloid neoplasms, of whom four (80%) had clonal haemopoiesis; 11 (16%) of 69 patients who did not develop therapy-related myeloid neoplasms had clonal haemopoiesis. In the external cohort, the cumulative incidence of therapy-related myeloid neoplasms at 10 years was significantly higher in patients with clonal haemopoiesis (29%, 95% CI 8-53) than in those without (0%, 0-0; p=0·0009). In a multivariate Fine and Gray model based on the external cohort, the presence of clonal haemopoiesis significantly increased the risk of therapy-related myeloid neoplasm development (hazard ratio 13·7, 95% CI 1·7-108·7; p=0·013).Preleukaemic clonal haemopoiesis is common in patients with therapy-related myeloid neoplasms at the time of their primary cancer diagnosis and before they have been exposed to treatment. Our results suggest that clonal haemopoiesis could be used as a predictive marker to identify patients with cancer who are at risk of developing therapy-related myeloid neoplasms. A prospective trial to validate this concept is warranted.Cancer Prevention Research Institute of Texas, Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer, NIH through MD Anderson Cancer Center Support Grant, and the MD Anderson MDS & AML Moon Shots Program." @default.
• W2557652172 created "2016-12-08" @default.
• W2557652172 creator A5000750846 @default.
• W2557652172 creator A5006025566 @default.
• W2557652172 creator A5008503600 @default.
• W2557652172 creator A5010663972 @default.
• W2557652172 creator A5010786159 @default.
• W2557652172 creator A5044622369 @default.
• W2557652172 creator A5049023530 @default.
• W2557652172 creator A5050532547 @default.
• W2557652172 creator A5051949215 @default.
• W2557652172 creator A5052077731 @default.
• W2557652172 creator A5057822243 @default.
• W2557652172 creator A5061026876 @default.
• W2557652172 creator A5064752432 @default.
• W2557652172 creator A5066957198 @default.
• W2557652172 creator A5069926299 @default.
• W2557652172 creator A5070455368 @default.
• W2557652172 creator A5071817116 @default.
• W2557652172 creator A5083934445 @default.
• W2557652172 creator A5090372170 @default.
• W2557652172 creator A5090435894 @default.
• W2557652172 date "2017-01-01" @default.
• W2557652172 modified "2023-10-15" @default.
• W2557652172 title "Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study" @default.
• W2557652172 cites W1497143314 @default.
• W2557652172 cites W1933695467 @default.
• W2557652172 cites W1964462241 @default.
• W2557652172 cites W1984882433 @default.
• W2557652172 cites W1985823023 @default.
• W2557652172 cites W1988340527 @default.
• W2557652172 cites W1990839427 @default.
• W2557652172 cites W1992826811 @default.
• W2557652172 cites W1994791499 @default.
• W2557652172 cites W1998367819 @default.
• W2557652172 cites W2000253139 @default.
• W2557652172 cites W2000738792 @default.
• W2557652172 cites W2011957619 @default.
• W2557652172 cites W2020069812 @default.
• W2557652172 cites W2049370950 @default.
• W2557652172 cites W2057858099 @default.
• W2557652172 cites W2066689762 @default.
• W2557652172 cites W2066891682 @default.
• W2557652172 cites W2072297806 @default.
• W2557652172 cites W2072467180 @default.
• W2557652172 cites W2073440691 @default.
• W2557652172 cites W2075877031 @default.
• W2557652172 cites W2084880955 @default.
• W2557652172 cites W2090502412 @default.
• W2557652172 cites W2106169155 @default.
• W2557652172 cites W2115383163 @default.
• W2557652172 cites W2120502315 @default.
• W2557652172 cites W2126816979 @default.
• W2557652172 cites W2148305047 @default.
• W2557652172 cites W2149858388 @default.
• W2557652172 cites W2163067447 @default.
• W2557652172 cites W2313420578 @default.
• W2557652172 cites W2344551873 @default.
• W2557652172 cites W2511116391 @default.
• W2557652172 cites W36679969 @default.
• W2557652172 doi "https://doi.org/10.1016/s1470-2045(16)30626-x" @default.
• W2557652172 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5405697" @default.
• W2557652172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27923552" @default.
• W2557652172 hasPublicationYear "2017" @default.
• W2557652172 type Work @default.
• W2557652172 sameAs 2557652172 @default.
• W2557652172 citedByCount "276" @default.
• W2557652172 countsByYear W25576521722017 @default.
• W2557652172 countsByYear W25576521722018 @default.
• W2557652172 countsByYear W25576521722019 @default.
• W2557652172 countsByYear W25576521722020 @default.
• W2557652172 countsByYear W25576521722021 @default.
• W2557652172 countsByYear W25576521722022 @default.
• W2557652172 countsByYear W25576521722023 @default.
• W2557652172 crossrefType "journal-article" @default.
• W2557652172 hasAuthorship W2557652172A5000750846 @default.
• W2557652172 hasAuthorship W2557652172A5006025566 @default.
• W2557652172 hasAuthorship W2557652172A5008503600 @default.
• W2557652172 hasAuthorship W2557652172A5010663972 @default.
• W2557652172 hasAuthorship W2557652172A5010786159 @default.
• W2557652172 hasAuthorship W2557652172A5044622369 @default.
• W2557652172 hasAuthorship W2557652172A5049023530 @default.
• W2557652172 hasAuthorship W2557652172A5050532547 @default.
• W2557652172 hasAuthorship W2557652172A5051949215 @default.
• W2557652172 hasAuthorship W2557652172A5052077731 @default.
• W2557652172 hasAuthorship W2557652172A5057822243 @default.
• W2557652172 hasAuthorship W2557652172A5061026876 @default.
• W2557652172 hasAuthorship W2557652172A5064752432 @default.
• W2557652172 hasAuthorship W2557652172A5066957198 @default.
• W2557652172 hasAuthorship W2557652172A5069926299 @default.
• W2557652172 hasAuthorship W2557652172A5070455368 @default.
• W2557652172 hasAuthorship W2557652172A5071817116 @default.
• W2557652172 hasAuthorship W2557652172A5083934445 @default.
• W2557652172 hasAuthorship W2557652172A5090372170 @default.
• W2557652172 hasAuthorship W2557652172A5090435894 @default.
• W2557652172 hasBestOaLocation W25576521722 @default.
• W2557652172 hasConcept C109159458 @default.
• W2557652172 hasConcept C121608353 @default.

• next